Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~13 mi. (Orléans, France, +226 more cities)

Centre Hospitalier Regional du Orleans ( Site 0430)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~13 mi. (Orléans, France, +93 more cities)

Centre Hospitalier Regional du Orleans ( Site 0463)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

~51 mi. (La Chaussée-Saint-Victor, France, +84 more cities)

Site FR33016

CLDN18 Expression

Pancreatic Adenocarcinoma

gemcitabine, +2 more drugs

chemotherapy, +1 more type

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~73 mi. (Corbeil-Essonnes, France, +96 more cities)

Centre Hospitalier Sud Francilien

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~88 mi. (Villejuif, France, +144 more cities)

Gustave Roussy ( Site 1207)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~88 mi. (Villejuif, France, +176 more cities)

Gustave Roussy ( Site 2071)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~88 mi. (Villejuif, France, +140 more cities)

Hopital Paul Brousse ( Site 0182)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~88 mi. (Villejuif, France, +199 more cities)

Hopital Paul Brousse ( Site 0447)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~88 mi. (Villejuif, France, +207 more cities)

Institut Gustave Roussy ( Site 0926)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~88 mi. (Villejuif, France, +163 more cities)

Institut Gustave Roussy ( Site 0487)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~88 mi. (Villejuif, France, +150 more cities)

Institut Gustave Roussy ( Site 0353)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~88 mi. (Villejuif, France, +137 more cities)

Institut Gustave Roussy ( Site 0352)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy